<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(3)</volume><submitter>Gude MF</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>Physiologically, pregnancy-associated plasma protein-A (PAPP-A) serves to liberate bound IGF1 by enzymatic cleavage of IGF-binding proteins (IGFBPs), IGFBP4 in particular. Clinically, PAPP-A has been linked to cardiovascular disease (CVD). Stanniocalcin-2 (STC2) is a natural inhibitor of PAPP-A enzymatic activity, but its association with CVD is unsettled. Therefore, we examined associations between the STC2-PAPP-A-IGFBP4-IGF1 axis and all-cause mortality and CVD in patients with type 2 diabetes (T2D).&lt;h4>Design&lt;/h4>We followed 1284 participants with T2D from the ADDITION trial for 5 years.&lt;h4>Methods&lt;/h4>Circulating concentrations of STC2, PAPP-A, total and intact IGFBP4 and IGF1 and -2 were measured at inclusion. End-points were all-cause mortality and a composite CVD e</pubmed_abstract><journal>Endocrine connections</journal><pagination>e220451</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9986395</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The STC2-PAPP-A-IGFBP4-IGF1 axis and its associations to mortality and CVD in T2D.</pubmed_title><pmcid>PMC9986395</pmcid><pubmed_authors>Bjerre M</pubmed_authors><pubmed_authors>Hjortebjerg R</pubmed_authors><pubmed_authors>Sandbæk A</pubmed_authors><pubmed_authors>Charles MH</pubmed_authors><pubmed_authors>Gude MF</pubmed_authors><pubmed_authors>Witte DR</pubmed_authors><pubmed_authors>Frystyk J</pubmed_authors></additional><is_claimable>false</is_claimable><name>The STC2-PAPP-A-IGFBP4-IGF1 axis and its associations to mortality and CVD in T2D.</name><description>&lt;h4>Objective&lt;/h4>Physiologically, pregnancy-associated plasma protein-A (PAPP-A) serves to liberate bound IGF1 by enzymatic cleavage of IGF-binding proteins (IGFBPs), IGFBP4 in particular. Clinically, PAPP-A has been linked to cardiovascular disease (CVD). Stanniocalcin-2 (STC2) is a natural inhibitor of PAPP-A enzymatic activity, but its association with CVD is unsettled. Therefore, we examined associations between the STC2-PAPP-A-IGFBP4-IGF1 axis and all-cause mortality and CVD in patients with type 2 diabetes (T2D).&lt;h4>Design&lt;/h4>We followed 1284 participants with T2D from the ADDITION trial for 5 years.&lt;h4>Methods&lt;/h4>Circulating concentrations of STC2, PAPP-A, total and intact IGFBP4 and IGF1 and -2 were measured at inclusion. End-points were all-cause mortality and a composite CVD e</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Mar</publication><modification>2025-04-21T19:51:13.189Z</modification><creation>2025-02-18T23:26:15.906Z</creation></dates><accession>S-EPMC9986395</accession><cross_references><pubmed>36607154</pubmed><doi>10.1530/EC-22-0451</doi></cross_references></HashMap>